

Press Release

14 December 2021

Last day of trading in Cessatech's warrants of series TO 1 is today Tuesday 14 December 2021

Copenhagen, Denmark, 14 December 2021 – Tuesday, 14 December 2021, is the last day of trading in warrants of series TO 1 on Spotlight Stock Market. The warrants of series TO 1 were issued in connection with Cessatech A/S (“Cessatech” or the “Company”) IPO of units that took place in November/December 2020. Each (1) warrant of series TO 1 entitles the holder to subscribe for one (1) new share in Cessatech. Last day to exercise the warrants of series TO 1 and subscribe for shares is 16 December 2021. Note that the banks/nominees need to be notified well in advance before the exercise period ends.

Each (1) warrant of series TO 1 entitles the holder to subscribe for one (1) new share in Cessatech at a price of DKK 10.00 per share. Warrants of series TO 1 that have not been exercised by Thursday 16 December 2021 or sold by Tuesday 14 December 2021 will expire and therefore be worthless. Holders of warrants of series TO 1 need to take action and instruct their respective bank/nominee in due time before the last day in the exercise period. Note that the banks/nominees need to be notified well in advance before the exercise period ends.

Teaser and subscription form

Teaser and subscription forms are available on the websites of Cessatech (www.cessatech.com), Sedermera Fondkommission (www.sedermera.se) and Nordic Issuing (www.nordic-issuing.se).

For further information regarding the exercise of warrants, please contact:

Sedermera Fondkommission

Phone: +46 40 - 615 14 10

E-mail: info@sedermera.se

www.sedermera.se

Nordic Issuing

Phone: +46 (0)40-632 00 20

E-mail: info@nordic-issuing.se

www.nordic-issuing.se

For more information about Cessatech, please contact:

Jes Trygved, CEO

Phone: +45 9387 2309

E-mail: jes.trygved@cessatech.com

www.cessatech.com

About Cessatech.

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.